Source: Pharmaceutical Business Review

Prilenia: Prilenia Therapeutics plans MAA submission to CHMP for pridopidine

The submission is scheduled for mid-2024, following constructive pre-submission meetings with EU regulatory authorities. The company also plans to engage with the US Food and Drug Administration (FDA) The post Prilenia Therapeutics plans MAA submission to CHMP for pridopidine appeared first on Pharmaceutical Business review.

Read full article »

Prilenia's Competitors | Prilenia's News | Prilenia's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Michael R. Hayden

CEO Approval Rating

88/100

Prilenia is an Israel-based biotechnology company that develops and commercializes neuroprotective therapeutics for the treatment of neurodegenerative diseases.